All patients | IL-6<median | IL-6>median | IL-6R<median | IL-6R>median | |
N=258 | (≤28.6 pg/mL) | (>28.6 pg/mL) | (≤33.5 ng/mL) | (>33.5 ng/mL) | |
Baseline characteristics | |||||
Age (years) | 60 (53–67) | 57 (52–64) | 62 (55–69)** | 60 (53–66) | 62 (52–68) |
Male gender | 212 (82.2%) | 107 (82.9%) | 106 (82.8%) | 113 (85.0%) | 100 (80.6%) |
Body mass index (kg/m2) | 26.6 (24.4–29.2) | 27.1 (24.5–29.4) | 26.3 (24.2–28.9) | 26.3 (24.2–29.0) | 27.1 (24.9–29.3) |
Hypertension | 72 (27.9%) | 30 (23.3%) | 41 (32.0%) | 38 (28.6%) | 33 (26.6%) |
Hypercholesterolaemia | 25 (9.7%) | 15 (11.6%) | 9 (7.0%) | 15 (11.3%) | 9 (7.3%) |
Diabetes mellitus | 16 (6.2%) | 9 (7.0%) | 7 (5.5%) | 9 (6.8%) | 7 (5.6%) |
Current smoker | 130 (50.4%) | 65 (50.4%) | 65 (50.8%) | 68 (51.1%) | 62 (50.0%) |
Clinical characteristics | |||||
Time from symptom to PCI (min) | 187 (125–265) | 172 (118–249) | 197 (129–282) | 190 (119–272) | 184 (129–265) |
Anterior MI† | 126 (48.8%) | 53 (41.1%) | 73 (57.0%)* | 65 (48.9%) | 63 (49.2%) |
Ischaemic post-conditioning‡ | 129 (50.0%) | 64 (49.6%) | 64 (50.0%) | 67 (50.4%) | 61 (49.2%) |
Biochemical analyses | |||||
Peak troponin T (ng/L) | 5919 (3319–10463) | 4900 (2693–7751) | 7487 (4736–13061)*** | 6260 (3713–11244) | 5174 (2628–9882) |
Peak CRP (mg/L) | 20 (8–52) | 11 (5–23) | 41 (16–84)*** | 20 (8–48) | 18 (7–53) |
Admission NT-proBNP (pmol/L) | 9 (5–22) | 8 (4–20) | 12 (5–25)* | 8 (4–21) | 11 (5–23) |
Admission creatinine (μmol/L) | 70 (62–81) | 70 (61–81) | 72 (63–81) | 68 (61–81) | 73 (64–81) |
Admission haemoglobin (g/dL) | 13.4 (12.4–14.4) | 13.3 (12.3–14.5) | 13.6 (12.4–14.4) | 13.3 (12.3–14.3) | 13.6 (12.4–14.6) |
Admission cholesterol (mmol/L) | 5.1 (4.5–6.0) | 5.2 (4.6–6.1) | 5.1 (4.4–5.8) | 5.2 (4.6–5.9) | 5.1 (4.5–6.0) |
Admission glucose (mmol/L) | 8.0 (6.8–9.3) | 7.7 (6.5–8.9) | 8.1 (6.9–9.5)* | 8.0 (6.8–9.6) | 7.8 (6.8–9.6) |
HbA1c (%) | 6.0 (5.8–6.2) | 6.0 (5.7–6.2) | 6.0 (5.8–6.2) | 6.0 (5.8–6.2) | 6.0 (5.7–6.2) |
Data are presented as median, number (percentage) and range. IL-6 and IL-6R was measured at day 1 (median 18.3 hours after PCI).
Significant values are highlighted in bold.
*p<0.05, **p<0.01, ***p<0.001 for comparison between high and low IL-6 and IL-6R levels (>/≤median).
†Infarct localisation—anterior myocardial infarction (MI) versus inferior or posterior MI.
‡Treated with ischaemic post-conditioning.
CRP, C reactive protein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention.